Myriad Genetics Acquires Patent on Another Breast Cancer-Linked Gene
By Ayesha Ahmad,
BioNews
| 01. 23. 2012
Myriad Genetics, a leading US molecular diagnostic company, has been granted exclusive rights to an analysis of the RAD51C gene. Mutations of the gene have been associated with an increased risk for hereditary breast and ovarian cancer and the company now hopes to develop a commercial test for RAD51C.
Mark Capone, president of Myriad, said: 'This intellectual property will enhance our ability to provide patients and health care providers important information on a patient's predisposition to hereditary breast and ovarian cancer'.
Read more...
Image via Flickr.
Related Articles
By Annalee Armstrong, BioSpace | 09.11.2024
Complex gene therapies are starting to hit the market but all have faced the same reality: a tepid reception from the healthcare system and a cloudy path to profitability.
It can take about a year for a patient to go...
By Matthew Rozsa, Salon | 09.15.2024
When a person with a uterus decides to freeze their eggs, any number of things can go wrong. Ice crystal can form, killing an otherwise viable ovum. A fertilized egg may fail to properly implant, or the egg may...
By Sarah Kliff, The New York Times | 09.09.2024
Image by Stephen Andrews from Unsplash
Yale agreed on Monday to pay dozens of patients who had filed lawsuits claiming that they had endured excruciatingly painful egg retrieval procedures after a nurse at its fertility clinic secretly swapped their anesthesia...
By Ari Schulman, The New York Times | 09.09.2024
There was immediate backlash when Alabama’s Supreme Court ruled in February that embryos created through in vitro fertilization qualified as children under the state’s wrongful death law. But it was a backlash as much from the right as from the...